Eli Lilly & Co. (LLY) & Incyte (INCY) Report Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/17/2026

1. FLNC
2. GNRC
3. CRM
4. SPY
5. BCBP
6. META
7. A
8. LSCC
9. SNAP
10. OM

Go back to Eli Lilly & Co. (LLY) & Incyte (INCY) Report Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib
Incyte Genomics, Inc. (NASDAQ: INCY) Delayed: 124.75 --0 (-0%)
Previous Close $124.75    52 Week High $118.49 
Open $124.75    52 Week Low $55.00 
Day High $124.75    P/E N/A 
Day Low $124.75    EPS $-0.56 
Volume 176       

Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1137.82 --0 (-0%)
Previous Close $1137.82    52 Week High $88.16 
Open $1137.82    52 Week Low $67.88 
Day High $1137.82    P/E 263.38 
Day Low $1137.82    EPS $4.32 
Volume 3,300